145 related articles for article (PubMed ID: 28679301)
1. TP53 in adult acute lymphoblastic leukemia.
Salmoiraghi S; Rambaldi A; Spinelli O
Leuk Lymphoma; 2018 Apr; 59(4):778-789. PubMed ID: 28679301
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
3. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
[No Abstract] [Full Text] [Related]
4. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
5. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Pane F; Cimino G; Izzo B; Camera A; Vitale A; Quintarelli C; Picardi M; Specchia G; Mancini M; Cuneo A; Mecucci C; Martinelli G; Saglio G; Rotoli B; Mandelli F; Salvatore F; Foà R;
Leukemia; 2005 Apr; 19(4):628-35. PubMed ID: 15744351
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
7. A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.
Capria S; Molica M; Mohamed S; Bianchi S; Moleti ML; Trisolini SM; Chiaretti S; Testi AM
Expert Rev Hematol; 2020 Jul; 13(7):755-769. PubMed ID: 32419532
[TBL] [Abstract][Full Text] [Related]
8. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia.
Scrideli CA; de Paula Queiróz R; Bernardes JE; Defavery R; Valera ET; Tone LG
Leuk Res; 2006 Aug; 30(8):1049-52. PubMed ID: 16406015
[TBL] [Abstract][Full Text] [Related]
9. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Koehler R; Bartram CR
Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.
Chiaretti S; Brugnoletti F; Tavolaro S; Bonina S; Paoloni F; Marinelli M; Patten N; Bonifacio M; Kropp MG; Sica S; Guarini A; Foà R
Haematologica; 2013 May; 98(5):e59-61. PubMed ID: 23403321
[No Abstract] [Full Text] [Related]
11. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
12. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
[TBL] [Abstract][Full Text] [Related]
14. [Acute leukemia in adults].
Eigendorff E; Hochhaus A
Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
[TBL] [Abstract][Full Text] [Related]
15. [Acute lymphoblastic leukemia in the adult].
Gökbuget N
Dtsch Med Wochenschr; 2011 Dec; 136(48):2466-9. PubMed ID: 22109577
[No Abstract] [Full Text] [Related]
16. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
18. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
[TBL] [Abstract][Full Text] [Related]
19. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
[TBL] [Abstract][Full Text] [Related]
20. High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.
Cruz-Rodriguez N; Combita AL; Enciso LJ; Quijano SM; Pinzon PL; Lozano OC; Castillo JS; Li L; Bareño J; Cardozo C; Solano J; Herrera MV; Cudris J; Zabaleta J
J Exp Clin Cancer Res; 2016 Apr; 35():64. PubMed ID: 27044543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
